ATE516345T1 - Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen - Google Patents

Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen

Info

Publication number
ATE516345T1
ATE516345T1 AT06762595T AT06762595T ATE516345T1 AT E516345 T1 ATE516345 T1 AT E516345T1 AT 06762595 T AT06762595 T AT 06762595T AT 06762595 T AT06762595 T AT 06762595T AT E516345 T1 ATE516345 T1 AT E516345T1
Authority
AT
Austria
Prior art keywords
ibdv
virus
particles
bursal disease
infectious bursal
Prior art date
Application number
AT06762595T
Other languages
English (en)
Inventor
Aguirre Jose Francisco Ctro Rodroeguez
Castan Jose Ruiz
Gamez Irene Saugar
Blanco Ana Maria Ona
Fern Ndez-Alba Juan Ramon Rodroeguez
Original Assignee
Consejo Superior Investigacion
Bionostra S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Bionostra S L filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE516345T1 publication Critical patent/ATE516345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06762595T 2005-07-15 2006-07-14 Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen ATE516345T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501733A ES2310062B1 (es) 2005-07-15 2005-07-15 Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
PCT/EP2006/006915 WO2007009673A1 (en) 2005-07-15 2006-07-14 Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications

Publications (1)

Publication Number Publication Date
ATE516345T1 true ATE516345T1 (de) 2011-07-15

Family

ID=37662111

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06762595T ATE516345T1 (de) 2005-07-15 2006-07-14 Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen

Country Status (9)

Country Link
US (1) US7476387B2 (de)
EP (1) EP1904626B1 (de)
JP (1) JP5713533B2 (de)
CN (1) CN101278043A (de)
AT (1) ATE516345T1 (de)
AU (1) AU2006271978B2 (de)
CA (1) CA2615468C (de)
ES (2) ES2310062B1 (de)
WO (1) WO2007009673A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2093281A1 (de) * 2008-02-19 2009-08-26 Kapsid Link, S.L. Proteinnanoträger, Verfahren zu ihrer Herstellung und Anwendungen
PL2288618T3 (pl) * 2008-05-09 2018-02-28 Chimera Pharma S.L.U. Chimeryczne białka fuzyjne oraz cząstki wirusopodobne z białka vp2 birnawirusa
ES2667052T3 (es) * 2009-11-06 2018-05-09 Chimera Pharma, S. L. U. Vacunas para el tratamiento de neoplasias a partir de capsides virales de birnavirus conteniendo antigenos del virus del papiloma humano
WO2011054995A2 (es) 2009-11-06 2011-05-12 Chimera Pharma, S. L. U. VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE
TWI571512B (zh) 2011-11-03 2017-02-21 辛提奈斯特治療公司 抗原類及針對人腸病毒之疫苗類
EP2870238A4 (de) 2012-07-05 2016-03-09 Ohio State Innovation Foundation Zusammensetzungen und verfahren in zusammenhang mit viralen impfstoffen
US10086062B2 (en) 2012-07-05 2018-10-02 Ohio State Innovation Foundation Infectious pancreatic necrosis virus (IPNV) vaccine compositions
WO2015101666A1 (en) * 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
CN107034198B (zh) 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CN108624611A (zh) * 2018-05-15 2018-10-09 武汉科前生物股份有限公司 传染性法氏囊病毒病毒样颗粒的制备及其应用
WO2023062182A1 (en) * 2021-10-15 2023-04-20 Aquilón Cyl, S.L. Vaccine compositions against bovine viral diarrhea virus
CN114058524A (zh) * 2021-10-28 2022-02-18 复旦大学 一种法氏囊亚病毒颗粒疫苗及其制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3585578D1 (de) 1984-06-18 1992-04-16 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
US5614409A (en) 1989-05-30 1997-03-25 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
US5641490A (en) 1991-03-07 1997-06-24 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
WO1992022575A1 (en) 1991-06-19 1992-12-23 Sri International M-protein peptides of influenza virus as antiviral agents
US5658572A (en) 1991-07-26 1997-08-19 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
CA2110505A1 (en) 1991-07-26 1993-02-18 Enzo Paoletti Infectious bursal disease virus recombinant poxvirus vaccine
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
JPH05194597A (ja) 1991-12-20 1993-08-03 Nippon Seibutsu Kagaku Kenkyusho 防御抗原性を有する伝染性ファブリキウス嚢病ウイルス（ｉｂｄｖ）の粒子製造法
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
EP0783038B1 (de) 1996-01-02 2007-04-04 Institut Pasteur Rekombinante virale Pseudopartikeln und deren Verwendung als Impfstoff oder als antitumorale Wirkstoff
US5871744A (en) 1996-09-05 1999-02-16 University Of Maryland-Biotechnology Inst. Method for generating birnavirus from synthetic RNA transcripts
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
EP0861665A1 (de) 1997-02-03 1998-09-02 Dimminaco Ag/Sa/Ltd. Vakzine gegen Infektiöse Bursitis
EP0980257A1 (de) 1997-05-01 2000-02-23 Chiron Corporation Verwendung von virusähnlichen partikeln als adjuvantien
CA2238659C (en) 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
EP0887412B1 (de) 1997-05-26 2003-10-15 Akzo Nobel N.V. Rekombinanter Birnavirusimpfstoff
US6596280B1 (en) 1997-07-31 2003-07-22 University Of Maryland Biotechnology Institute Method for generating birnavirus from synthetic RNA transcripts
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6231868B1 (en) 1997-09-30 2001-05-15 University Of Maryland-Biotechnology Institute Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6406843B1 (en) 1998-02-27 2002-06-18 University Of Arkansas Poultry virus isolates and method
WO1999050419A2 (en) 1998-03-31 1999-10-07 University Of Maryland Biotechnology Institute A method for generating nonpathogenic, infectious pancreatic necrosis virus (ipnv) from synthetic rna transcripts
US6114112A (en) 1998-05-21 2000-09-05 The Ohio State University Method of making immunogenic compositions for infectious bursal disease virus
ATE314095T1 (de) * 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
HUP9802974A1 (hu) 1998-12-19 2000-09-28 Mezőgazdasági Biotechnológiai Kutatóközpont Fertőző bursitis elleni DNS-vakcina
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6528063B2 (en) * 1999-01-04 2003-03-04 Rahan Meristem Recombinant vaccines against IBDV
EP1069187A1 (de) 1999-07-14 2001-01-17 Stichting Dienst Landbouwkundig Onderzoek Mosaik-Virus der infectiösen Bursal-Krankheit enthaltender Impfstoff
FR2806087B1 (fr) 2000-03-07 2002-10-18 Agronomique Inst Nat Rech Particules pseudovirales de rotavirus et leur utilisation pour vectoriser des proteines ou des acides nucleiques
HK1052949B (en) 2000-04-14 2011-04-29 Wisconsin Alumni Research Foundation Viruses comprising mutated ion channel protein
US20020165176A1 (en) 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
CA2407897A1 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
WO2001097839A1 (en) 2000-06-19 2001-12-27 Rahan Meristem Recombinant vaccines against infectious bursal disease virus
JP5008244B2 (ja) 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
EP2088197B8 (de) * 2000-10-02 2016-07-20 ID Biomedical Corporation of Quebec Haemophilus influenzae-Antigene und entsprechende DNA-Fragmente
WO2002074795A2 (en) 2001-01-18 2002-09-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
FR2824327B1 (fr) * 2001-05-02 2003-07-11 Agronomique Inst Nat Rech Particules pseudovirales de birnavirus
WO2002096940A2 (en) 2001-05-31 2002-12-05 Id-Lelystad, Institut Voor Dierhouderij En Diergezondheid B.V. Attenuated very virulent infectious bursal disease virus
US6936256B2 (en) 2001-08-10 2005-08-30 University Of Maryland Biotechnology Institute Sub-unit vaccine for infectious pancreatic necrosis virus
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
ATE543906T1 (de) * 2002-02-11 2012-02-15 Id Biomedical Corp Antigen von streptococcus aus der b-gruppe
PL209994B1 (pl) 2002-03-01 2011-11-30 Intervet Int Bv Wariant wirusa zakaźnego zapalenia torby Fabrycjusza (IBDV), szczepionki, sposób wytwarzania wariantu IBDV, sposób wytwarzania szczepionek, zastosowanie wariantów IBDV
DK1506222T3 (da) 2002-05-17 2009-07-06 Univ Cape Town Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne
CA2488856A1 (en) 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
CA2490866A1 (en) 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
EP2351770A1 (de) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molekulare Antigen-Anordnung durch Verwendung eines Virus ähnlichen Partikels vom Virus ap205
WO2004025263A2 (en) 2002-09-16 2004-03-25 Advanced Bionutrition Corporation Protein and peptide expression for passive immunity
KR20050114225A (ko) 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
ES2217967B1 (es) 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
AU2004249133B2 (en) 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
EP1644034B1 (de) 2003-07-10 2011-01-12 Cytos Biotechnology AG Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
ES2307345B1 (es) 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2242542B1 (es) 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
CA2580208A1 (en) 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
US7244432B2 (en) 2004-12-08 2007-07-17 University Of Maryland Biotechnology Institute Infectious bursal disease virus (IBDV) variant from Georgia

Also Published As

Publication number Publication date
AU2006271978A1 (en) 2007-01-25
ES2310062B1 (es) 2009-11-13
ES2310062A1 (es) 2008-12-16
ES2371833T3 (es) 2012-01-10
US7476387B2 (en) 2009-01-13
WO2007009673A1 (en) 2007-01-25
US20070015243A1 (en) 2007-01-18
JP5713533B2 (ja) 2015-05-07
CN101278043A (zh) 2008-10-01
CA2615468A1 (en) 2007-01-25
EP1904626A1 (de) 2008-04-02
AU2006271978B2 (en) 2012-08-02
CA2615468C (en) 2015-04-14
EP1904626B1 (de) 2011-07-13
JP2009501012A (ja) 2009-01-15

Similar Documents

Publication Publication Date Title
IL189313A (en) Virus-like particles as virus-paramixo vaccines, a method for their preparation and use
ATE516345T1 (de) Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
NZ595736A (en) Chimeric viruses presenting non-native surface proteins and uses thereof
WO2007011904A3 (en) Recombinant flu vaccines
EA200100619A1 (ru) Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AU2016219738A1 (en) Designer peptide-based PCV2 vaccine
MX2009000650A (es) Vacunas para malaria.
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2004001051A3 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO2003040187A1 (en) Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
EP1331271A4 (de) Die polypeptidfragmente des hepatitis-e-virus, die diese fragmente enthaltende impfstoffzusammensetzung und die diagnostischen kits
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
ATE424450T1 (de) Chimärische leere capside des ibdv (infectious bursal disease virus), gewinnungsverfahren und anwendungen
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
MY207280A (en) Polyvalent immunogenicity composition for human papillomavirus
ATE534666T1 (de) Antikörper gegen den hepatitis c-virus e1e2 komplex und pharmazeutische zusammensetzungen
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
RU2007129962A (ru) Универсальная вакцина против вируса гриппа птиц
CL2010001175A1 (es) Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
WO2002088339A3 (fr) Particules pseudovirales de birnavirus
ATE286507T1 (de) Dna kodierend für das strukturalprotein-1 vom infektiösen lachs anämie virus und ihre verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties